我们通过肿瘤细胞和树突状细胞的融合（Hsp70.PC-F），在分离Hsp70肽复合物后，建立了一种增强型分子伴侣疫苗。在这种方法中，肿瘤抗原通过细胞融合过程引入到树突状细胞的抗原处理机制中，因此我们可以获得被树突状细胞处理过的抗原性肿瘤肽或其中间体。我们的结果表明，与仅来自肿瘤细胞的制备相比，Hsp70.PC-F具有增强的免疫原性，因此构成了一种改进的分子伴侣蛋白基肿瘤疫苗的配方。© 2023. 作者，独家许可给Springer Science+Business Media，LLC，属于Springer Nature。

We have developed an enhanced molecular chaperone-based vaccine through rapid isolation of Hsp70 peptide complexes after the fusion of tumor and dendritic cells (Hsp70.PC-F). In this approach, the tumor antigens are introduced into the antigen-processing machinery of dendritic cells through the cell fusion process, and thus we can obtain antigenic tumor peptides or their intermediates that have been processed by dendritic cells. Our results show that Hsp70.PC-F has increased immunogenicity compared to preparations from tumor cells alone and therefore constitutes an improved formulation of the chaperone protein-based tumor vaccine.© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.